All In Biotech

Drug Trial Radar · NCT01742299

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

155

Actual

Start

Mar 26, 2013

Primary completion

Apr 20, 2026

Study completion Apr 20, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 5, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase IV, open-label, multicenter roll-over study evaluated the long-term safety of imatinib in patients who had completed a previous Novartis-sponsored imatinib study and were considered by the investigator to continue benefiting from treatment.

Conditions

  • GIST and CML

Interventions

  • imatinib mesylateDrug

    Imatinib was administered orally at a total daily dose ranging from 100 to 800 milligrams. The starting dose was the same as the dose received in the parent study and could subsequently be adjusted based on the investigator's clinical judgment. Imatinib was supplied as 100 milligram and 400 milligram tablets and was administered once daily or, for patients receiving 800 milligrams daily, as 400 milligrams twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months)

Locations

29 sites in 11 countries. Site status is shown where the registry gives one.

  • University of California LA

    Los Angeles, California

  • Northwestern University

    Chicago, Illinois

  • Sidney Kimmel CCC At JH

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Weill Cornell Medical Center

    New York, New York

  • Oregon Health Sciences University

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Guangzhou, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, China

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Poitiers, France

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Bucharest, Romania

  • Novartis Investigative Site

    Cluj-Napoca, Cluj, Romania

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Basel, Switzerland

  • Novartis Investigative Site

    Bangkok, Thailand

  • Novartis Investigative Site

    Ankara, Sihhiye Altindag, Turkey (Türkiye)

  • Novartis Investigative Site

    Manchester, United Kingdom

  • Novartis Investigative Site

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.